Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Second generation antidysrhythmic agents.

Critical Care Nursing Clinics of North America

|June 1, 1989

Summary

This summary is machine-generated.

New antidysrhythmic drugs effectively treat ventricular arrhythmias with fewer daily doses. However, their risk-benefit ratio requires careful assessment, as they do not prevent sudden cardiac death and have predictable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intervention strategies for microbial therapeutics in cancer immunotherapy.

Immuno-oncology technology·2022

Same author

Characterization of biochars and dissolved organic matter phases obtained upon hydrothermal carbonization of Elodea nuttallii.

Bioresource technology·2015

Same author

Organic breakdown products resulting from hydrothermal carbonization of brewer's spent grain.

Chemosphere·2015

Same author

Hydrothermal carbonization of poly(vinyl chloride).

Chemosphere·2014

Same author

Characterization of biocoals and dissolved organic matter phases obtained upon hydrothermal carbonization of brewer's spent grain.

Bioresource technology·2014

Same author

Organic compounds in olive mill wastewater and in solutions resulting from hydrothermal carbonization of the wastewater.

Chemosphere·2013

Same journal

A New Era of Nursing Innovation.

Critical care nursing clinics of North America·2026

Same journal

Advancing Outcomes Through Innovation.

Critical care nursing clinics of North America·2026

Same journal

The Arc of Nurse Anesthesia: From Battlefield Origins to Future Innovation.

Critical care nursing clinics of North America·2026

Same journal

A Sepsis-Informed Model of Accelerated Aging.

Critical care nursing clinics of North America·2026

Same journal

TeleCritical Care Reimagined: Efficiency Through Digital Communication Application.

Critical care nursing clinics of North America·2026

Same journal

Impacts and Outcomes of Intensive Care Unit Design.

Critical care nursing clinics of North America·2026

See all related articles

Area of Science:

Cardiology
Pharmacology

Background:

New antidysrhythmic agents are emerging for ventricular arrhythmias.
Assessing their risk-benefit ratio is crucial before clinical adoption.

Purpose of the Study:

To evaluate the efficacy and safety of new antidysrhythmic agents.
To compare the effectiveness of different drug classes for arrhythmias.

Main Methods:

Review of clinical data and trials for new antidysrhythmic agents.
Analysis of pharmacokinetic profiles and adverse effect data.
Comparison of Class IC and Class IB agents, and Class IA agents.

Main Results:

New agents are effective for ventricular and some supraventricular dysrhythmias.

Related Experiment Videos

Oral administration and unique pharmacokinetics allow less frequent dosing.

Adverse effects are typically gastrointestinal and central nervous system related, often reversible.

Class IC agents (encainide, flecainide, propafenone) are considered first-line for lethal dysrhythmias.

Class IB agents show enhanced efficacy with reduced side effects when combined with Class IA agents (quinidine, procainamide).

Conclusions:

New antidysrhythmics offer improved treatment options for various arrhythmias.
Careful risk-benefit assessment is necessary due to potential adverse effects.
Current evidence does not support their use for preventing sudden cardiac death, though research is ongoing.